Relevant bibliographies by topics / EV-based therapeutics

Academic literature on the topic 'EV-based therapeutics'

Author: Grafiati
Published: 10 December 2022
Last updated: 29 January 2023

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Contents

Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'EV-based therapeutics.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Journal articles on the topic "EV-based therapeutics"

1

Williams, Katherine B., and Nicole P. Ehrhart. "Regenerative medicine 2.0: extracellular vesicle–based therapeutics for musculoskeletal tissue regeneration." Journal of the American Veterinary Medical Association 260, no. 7 (April 1, 2022): 683–89. http://dx.doi.org/10.2460/javma.22.02.0060.

Full text
Abstract:
In recent years, extracellular vesicles (EVs) have emerged as prominent mediators of the homeostasis, repair, and regeneration of musculoskeletal tissues including bone, skeletal muscle, and cartilage. Accordingly, the therapeutic potential of EVs for regenerative medicine applications has not gone unnoticed. The use of EVs for the treatment of musculoskeletal injury and disease in veterinary species is a nascent but rapidly expanding area of research. Recent studies in this area have demonstrated the safety and feasibility of EV products in dogs and horses. While early clinical responses to EV-based therapeutics in companion animals have been favorable, more rigorously designed, sufficiently powered, and placebo-controlled clinical trials are required to fully elucidate the clinical benefits and best-use scenarios for EV therapeutics in veterinary medicine. Additionally, clinical translation of EV-based therapeutics will require Good Manufacturing Practice–compliant methods to scale up and purify EV products. Despite these challenges, EVs hold great promise in the regenerative medicine landscape, particularly in the treatment of musculoskeletal injury and disease in companion animals.
APA, Harvard, Vancouver, ISO, and other styles
2

OCHIYA, Takahiro. "Development of extracellular vesicle (EV)-based diagnostics and therapeutics." Translational and Regulatory Sciences 2, no. 3 (2020): 80–83. http://dx.doi.org/10.33611/trs.2020-016.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Klyachko, Natalia L., Camryn J. Arzt, Samuel M. Li, Olesia A. Gololobova, and Elena V. Batrakova. "Extracellular Vesicle-Based Therapeutics: Preclinical and Clinical Investigations." Pharmaceutics 12, no. 12 (December 1, 2020): 1171. http://dx.doi.org/10.3390/pharmaceutics12121171.

Full text
Abstract:
Drug nanoformulations hold remarkable promise for the efficient delivery of therapeutics to a disease site. Unfortunately, artificial nanocarriers, mostly liposomes and polymeric nanoparticles, show limited applications due to the unfavorable pharmacokinetics and rapid clearance from the blood circulation by the reticuloendothelial system (RES). Besides, many of them have high cytotoxicity, low biodegradability, and the inability to cross biological barriers, including the blood brain barrier. Extracellular vesicles (EVs) are novel candidates for drug delivery systems with high bioavailability, exceptional biocompatibility, and low immunogenicity. They provide a means for intercellular communication and the transmission of bioactive compounds to targeted tissues, cells, and organs. These features have made them increasingly attractive as a therapeutic platform in recent years. However, there are many obstacles to designing EV-based therapeutics. In this review, we will outline the main hurdles and limitations for therapeutic and clinical applications of drug loaded EV formulations and describe various attempts to solve these problems.
APA, Harvard, Vancouver, ISO, and other styles
4

Nelson, Bryant C., Samantha Maragh, Ionita C. Ghiran, Jennifer C. Jones, Paul C. DeRose, Elzafir Elsheikh, Wyatt N. Vreeland, and Lili Wang. "Measurement and standardization challenges for extracellular vesicle therapeutic delivery vectors." Nanomedicine 15, no. 22 (September 2020): 2149–70. http://dx.doi.org/10.2217/nnm-2020-0206.

Full text
Abstract:
Extracellular vesicles (EVs), such as exosomes and microvesicles, are nonreplicating lipid bilayer particles shed by most cell types which have the potential to revolutionize the development and efficient delivery of clinical therapeutics. This article provides an introduction to the landscape of EV-based vectors under development for the delivery of protein- and nucleic acid-based therapeutics. We highlight some of the most pressing measurement and standardization challenges that limit the translation of EVs to the clinic. Current challenges limiting development of EVs for drug delivery are the lack of: standardized cell-based platforms for the production of EV-based therapeutics; EV reference materials that allow researchers/manufacturers to validate EV measurements and standardized measurement systems for determining the molecular composition of EVs.
APA, Harvard, Vancouver, ISO, and other styles
5

Dang, Xuan T. T., Jayasinghe Migara Kavishka, Daniel Xin Zhang, Marco Pirisinu, and Minh T. N. Le. "Extracellular Vesicles as an Efficient and Versatile System for Drug Delivery." Cells 9, no. 10 (September 29, 2020): 2191. http://dx.doi.org/10.3390/cells9102191.

Full text
Abstract:
Despite the recent advances in drug development, the majority of novel therapeutics have not been successfully translated into clinical applications. One of the major factors hindering their clinical translation is the lack of a safe, non-immunogenic delivery system with high target specificity upon systemic administration. In this respect, extracellular vesicles (EVs), as natural carriers of bioactive cargo, have emerged as a promising solution and can be further modified to improve their therapeutic efficacy. In this review, we provide an overview of the biogenesis pathways, biochemical features, and isolation methods of EVs with an emphasis on their many intrinsic properties that make them desirable as drug carriers. We then describe in detail the current advances in EV therapeutics, focusing on how EVs can be engineered to achieve improved target specificity, better circulation kinetics, and efficient encapsulation of therapeutic payloads. We also identify the challenges and obstacles ahead for clinical translation and provide an outlook on the future perspective of EV-based therapeutics.
APA, Harvard, Vancouver, ISO, and other styles
6

Gilligan, Katie E., and Róisín M. Dwyer. "Extracellular Vesicles for Cancer Therapy: Impact of Host Immune Response." Cells 9, no. 1 (January 16, 2020): 224. http://dx.doi.org/10.3390/cells9010224.

Full text
Abstract:
In recent times, extracellular vesicles (EVs) have come under the spotlight as potential therapeutics for cancer, due to the relative ease of manipulation of contents and potential for tumor targeting. The use of EVs as delivery vehicles may bypass some of the negative effects associated with cell-based carriers, and there has been a major focus on defining EV subtypes, establishing transparent nomenclature, and isolation and characterization techniques. EVs are believed to be a fingerprint of the secreting cell and so researchers harness the positive aspects of a particular cell of origin, and can then further modify EV contents to improve therapeutic efficacy. In this review, we highlight studies employing EVs as cancer therapeutics that have reported on immune response. As we rapidly advance towards potential application in the clinical setting, the question of immune response to EV administration in the cancer setting has become critically important.
APA, Harvard, Vancouver, ISO, and other styles
7

Abreu, Catarina M., Bruno Costa-Silva, Rui L. Reis, Subhas C. Kundu, and David Caballero. "Microfluidic platforms for extracellular vesicle isolation, analysis and therapy in cancer." Lab on a Chip 22, no. 6 (2022): 1093–125. http://dx.doi.org/10.1039/d2lc00006g.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Ovchinnikova, Leyla A., Ioanna N. Filimonova, Maria Y. Zakharova, Dmitriy S. Balabashin, Teimour K. Aliev, Yakov A. Lomakin, and Alexander G. Gabibov. "Targeting Extracellular Vesicles to Dendritic Cells and Macrophages." Acta Naturae 13, no. 3 (November 15, 2021): 114–21. http://dx.doi.org/10.32607/actanaturae.11478.

Full text
Abstract:
Targeting protein therapeutics to specific cells and tissues is a major challenge in modern medicine. Improving the specificity of protein therapeutic delivery will significantly enhance efficiency in drug development. One of the promising tools for protein delivery is extracellular vesicles (EVs) that are enveloped by a complex lipid bilayer. EVs are secreted by almost all cell types and possess significant advantages: biocompatibility, stability, and the ability to penetrate the bloodbrain barrier. Overexpression of the vesicular stomatitis virus protein G (VSV-G) was shown to promote EV formation by the producer cell. We have developed an EV-based system for targeted delivery of protein cargoes to antigen-presenting cells (APCs). In this study, we show that attachment of a recombinant llama nanobody -CD206 to the N-terminus of a truncated VSV-G increases the selectivity of EV cargo delivery mainly to APCs. These results highlight the outstanding technological and biomedical potential of EV-based delivery systems for correcting the immune response in patients with autoimmune, viral, and oncological diseases.
APA, Harvard, Vancouver, ISO, and other styles
9

Brown, Thomas J., and Victoria James. "The Role of Extracellular Vesicles in the Development of a Cancer Stem Cell Microenvironment Niche and Potential Therapeutic Targets: A Systematic Review." Cancers 13, no. 10 (May 18, 2021): 2435. http://dx.doi.org/10.3390/cancers13102435.

Full text
Abstract:
Cancer stem cells (CSCs) have increasingly been shown to be a crucial element of heterogenous tumors. Although a relatively small component of the population, they increase the resistance to treatment and the likelihood of recurrence. In recent years, it has been shown, across multiple cancer types (e.g., colorectal, breast and prostate), that reciprocal communication between cancer and the microenvironment exists, which is, in part, facilitated by extracellular vesicles (EVs). However, the mechanisms of this method of communication and its influence on CSC populations is less well-understood. Therefore, the aim of this systematic review is to determine the evidence that supports the role of EVs in the manipulation of the tumor microenvironment to promote the survival of CSCs. Embase and PubMed were used to identify all studies on the topic, which were screened using PRISMA guidelines, resulting in the inclusion of 16 studies. These 16 studies reported on the EV content, pathways altered by EVs and therapeutic targeting of CSC through EV-mediated changes to the microenvironment. In conclusion, these studies demonstrated the role of EV-facilitated communication in maintaining CSCs via manipulation of the tumor microenvironment, demonstrating the potential of creating therapeutics to target CSCs. However, further works are needed to fully understand the targetable mechanisms upon which future therapeutics can be based.
APA, Harvard, Vancouver, ISO, and other styles
10

Haney, Matthew J., Yuling Zhao, Yeon S. Jin, and Elena V. Batrakova. "Extracellular Vesicles as Drug Carriers for Enzyme Replacement Therapy to Treat CLN2 Batten Disease: Optimization of Drug Administration Routes." Cells 9, no. 5 (May 20, 2020): 1273. http://dx.doi.org/10.3390/cells9051273.

Full text
Abstract:
CLN2 Batten disease (BD) is one of a broad class of lysosomal storage disorders that is characterized by the deficiency of lysosomal enzyme, TPP1, resulting in a build-up of toxic intracellular storage material in all organs and subsequent damage. A major challenge for BD therapeutics is delivery of enzymatically active TPP1 to the brain to attenuate progressive loss of neurological functions. To accomplish this daunting task, we propose the harnessing of naturally occurring nanoparticles, extracellular vesicles (EVs). Herein, we incorporated TPP1 into EVs released by immune cells, macrophages, and examined biodistribution and therapeutic efficacy of EV-TPP1 in BD mouse model, using various routes of administration. Administration through intrathecal and intranasal routes resulted in high TPP1 accumulation in the brain, decreased neurodegeneration and neuroinflammation, and reduced aggregation of lysosomal storage material in BD mouse model, CLN2 knock-out mice. Parenteral intravenous and intraperitoneal administrations led to TPP1 delivery to peripheral organs: liver, kidney, spleen, and lungs. A combination of intrathecal and intraperitoneal EV-TPP1 injections significantly prolonged lifespan in BD mice. Overall, the optimization of treatment strategies is crucial for successful applications of EVs-based therapeutics for BD.
APA, Harvard, Vancouver, ISO, and other styles
More sources

Dissertations / Theses on the topic "EV-based therapeutics"

1

Matsumoto, Akihiro. "Development of small extracellular vesicle-based therapeutics based on the elucidation and regulation of pharmacokinetic properties." Doctoral thesis, Kyoto University, 2020. http://hdl.handle.net/2433/253232.

Full text
Abstract:
付記する学位プログラム名: 充実した健康長寿社会を築く総合医療開発リーダー育成プログラム
京都大学
0048
新制・課程博士
博士(薬科学)
甲第22396号
薬科博第118号
新制||薬科||13(附属図書館)
京都大学大学院薬学研究科薬科学専攻
(主査)教授 髙倉 喜信, 教授 山下 富義, 教授 小野 正博
学位規則第4条第1項該当
Doctor of Pharmaceutical Sciences
Kyoto University
DFAM
APA, Harvard, Vancouver, ISO, and other styles

Conference papers on the topic "EV-based therapeutics"

1

Steiner, Nejc, Domen Vozel, and Saba Battelino. "Surface-Based Total Blood Volume Calculation for Platelet and Extracellular Vesicle-Rich Plasma and Gel Preparation by Us-ing a Mathematical Model." In Socratic Lectures 7. University of Lubljana Press, 2022. http://dx.doi.org/10.55295/psl.2022.d6.

Full text
Abstract:
Platelet- and extracellular vesicle-rich plasma (PVRP) and platelet- and extracellular vesicle-rich gel (PVRG) are blood-derived products gaining attraction in regenerative medicine. However, despite their reported good efficacy, their preparation protocols are too time-consum-ing. Moreover, patient-tailored preparation protocols are desired to optimise platelet and extra-cellular vesicle (EV) count in PVRP and PVRG. This scientific contribution presents a clinical implementation of mathematical model for calculation of the desired total blood volume for PVRG preparation. PVRG was prepared according to previously derived mathematical model of blood cell and EV sedimentation during centrifugation based on the patient's erythrocyte sedi-mentation rate (ESR) (Božič et al., 2021). We estimated the volume of blood required for the treat-ment of the surface area of the individual patient, prepared the PVRG accordingly and applied it to the patient’s wound. After six applications of 13 mL to 65 mL of PVRG, the osteoradi-onecrotic surface area decreased from 46 cm2 to 18 cm2, and infection was eradicated. The math-ematical modelling of total blood volume needed to prepare PVRG proved useful to prepare the therapeutic amount of PVRG and also optimized time for the PVRG preparation protocol. Keywords: Extracellular vesicles; Platelet-rich plasma; Regenerative medicine; Osteitis; Osteora-dionecrosis; Osteomyelitis; Temporal bone
APA, Harvard, Vancouver, ISO, and other styles
You might also be interested in the extended bibliographies on the topic 'EV-based therapeutics' for particular source types:
Journal articles
We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!

To the bibliography